A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

• Published in: Cancer research (Chicago, Ill.) Vol. 82; no. 20; pp. 3673 - 3686
• Main Authors: Nardone, Agostina, Qiu, Xintao, Spisak, Sandor, Nagy, Zsuzsanna, Feiglin, Ariel, Feit, Avery, Cohen Feit, Gabriela, Xie, Yingtian, Font-Tello, Alba, Guarducci, Cristina, Hermida-Prado, Francisco, Syamala, Sudeepa, Lim, Klothilda, Munoz Gomez, Miguel, Pun, Matthew, Cornwell, MacIntosh, Liu, Weihan, Ors, Aysegul, Mohammed, Hisham, Cejas, Paloma, Brock, Jane B, Freedman, Matthew L, Winer, Eric P, Fu, Xiaoyong, Schiff, Rachel, Long, Henry W, Metzger Filho, Otto, Jeselsohn, Rinath
• Format: Journal Article
• Language: English
• Published: United States 17.10.2022
• Subjects: Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Carcinoma, Ductal, Breast - pathology; Carcinoma, Lobular - drug therapy; Carcinoma, Lobular - genetics; Carcinoma, Lobular - metabolism; Chromatin - genetics; Drug Resistance, Neoplasm - genetics; Female; Humans; Prognosis; Receptors, Estrogen - metabolism; Tamoxifen - pharmacology; Tamoxifen - therapeutic use
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-21-3186

Most invasive lobular breast cancers (ILC) are of the luminal A subtype and are strongly hormone receptor-positive. Yet, ILC is relatively resistant to tamoxifen and associated with inferior long-term outcomes compared with invasive ductal cancers (IDC). In this study, we sought to gain mechanistic insights into these clinical findings that are not explained by the genetic landscape of ILC and to identify strategies to improve patient outcomes. A comprehensive analysis of the epigenome of ILC in preclinical models and clinical samples showed that, compared with IDC, ILC harbored a distinct chromatin state linked to gained recruitment of FOXA1, a lineage-defining pioneer transcription factor. This resulted in an ILC-unique FOXA1-estrogen receptor (ER) axis that promoted the transcription of genes associated with tumor progression and poor outcomes. The ILC-unique FOXA1-ER axis led to retained ER chromatin binding after tamoxifen treatment, which facilitated tamoxifen resistance while remaining strongly dependent on ER signaling. Mechanistically, gained FOXA1 binding was associated with the autoinduction of FOXA1 in ILC through an ILC-unique FOXA1 binding site. Targeted silencing of this regulatory site resulted in the disruption of the feed-forward loop and growth inhibition in ILC. In summary, ILC is characterized by a unique chromatin state and FOXA1-ER axis that is associated with tumor progression, offering a novel mechanism of tamoxifen resistance. These results underscore the importance of conducting clinical trials dedicated to patients with ILC in order to optimize treatments in this breast cancer subtype. A unique FOXA1-ER axis in invasive lobular breast cancer promotes disease progression and tamoxifen resistance, highlighting a potential therapeutic avenue for clinical investigations dedicated to this disease. See related commentary by Blawski and Toska, p. 3668.